NuCana (NCNA) Consolidated Net Income (2017 - 2025)
NuCana (NCNA) reported Consolidated Net Income of -$3.7 million for Q4 2025, down 209.57% on a YoY basis from $3.4 million in Q4 2024, and down 181.11% sequentially from -$1.3 million in Q3 2025.
NuCana (NCNA) Consolidated Net Income (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Consolidated Net Income data on file, last reported at -$3.7 million in Q4 2025.
- For the quarter ending Q4 2025, Consolidated Net Income fell 209.57% year-over-year to -$3.7 million; the trailing twelve-month figure through Dec 2025 stood at -$42.0 million (down 27.4% YoY), and the FY2025 full-year result was -$41.8 million, down 26.18% from the prior year.
- Consolidated Net Income slipped to -$3.7 million in Q4 2025, from -$1.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$1.2 million in Q4 2024 to a low of -$33.0 million in Q2 2025.
- A 5-year average of -$12.6 million and a median of -$12.0 million in 2023 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income surged 90.68% in 2024 and tumbled 209.57% in 2025, its largest moves.
- Tracing NCNA's Consolidated Net Income over 5 years: stood at -$24.0 million in 2021, then advanced by 8.42% to -$22.0 million in 2022, then surged by 41.86% to -$12.8 million in 2023, then surged by 90.68% to -$1.2 million in 2024, then plunged by 209.57% to -$3.7 million in 2025.
- Business Quant data shows NCNA's Consolidated Net Income at -$3.7 million in Q4 2025, -$1.3 million in Q3 2025, and -$33.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.68 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | -33.04 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -7.78 Mn |
| Jun 30, 2024 | -12.04 Mn |
| Mar 31, 2024 | -11.98 Mn |
| Dec 31, 2023 | -12.77 Mn |
| Sep 30, 2023 | -12.04 Mn |
| Jun 30, 2023 | -8.49 Mn |
| Mar 31, 2023 | -11.98 Mn |
| Dec 31, 2022 | -21.96 Mn |
| Sep 30, 2022 | -8.74 Mn |
| Jun 30, 2022 | -7.91 Mn |
| Mar 31, 2022 | -16.73 Mn |
| Dec 31, 2021 | -23.98 Mn |
| Sep 30, 2021 | -16.35 Mn |
| Jun 30, 2021 | -17.13 Mn |
| Mar 31, 2021 | -18.15 Mn |